← Patent Expiry Watch
October 20, 2026 · Patent expires December 6, 2044
ROMVIMZA (VIMSELTINIB): The 2044 Generic Opportunity Window
DECIPHERA PHARMACEUTICALS LLC's core patent 12528787 for VIMSELTINIB expires on December 6, 2044. Currently, zero generics exist for this oral capsule. No real litigation signal found.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.